20 Years of Pediatric Benchmarking in Germany and Austria: Age-Dependent Analysis of Longitudinal Follow-Up in 63,967 Children and Adolescents with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To investigate changes in diabetes treatment over the last two decades in three age-groups of children and adolescents with type 1 diabetes (T1D) from Germany and Austria. METHODS: 63,967 subjects (<18yr) with T1D documented between 1995 and 2014 from the DPV-database were included and stratified according to age (0.5-<6, 6-<12, 12-<18yr). Regression models were applied for insulin regimens (<3 and ≥4 injection time points/day, or continuous subcutaneous insulin infusion (CSII)), use of rapid- and long acting insulin analogues, NPH insulin, and frequency of self-monitoring of blood glucose (SMBG)/day. Models were adjusted for sex, diabetes duration, and migration background. P-value for trend was given. FINDINGS: The number of subjects with <3 injection time points/day decreased from 1995 to 2014 to <5% in all age-groups (p<0.0001). Proportion of patients with ≥4 injections/day increased until the early 2000s, and then declined until 2014. This trend was not found in 6-<12yr olds (p = 0.3403). CSII increased in all age-groups (p<0.0001) with the highest increase in children <6 years (from 0.4% to 79.2%), and the lowest increase in 12-<18 year olds (from 1.0% to 38.9%). NPH insulin decreased in all age-groups (p<0.0001). Insulin analogues, especially rapid-acting, became more frequent in all age-groups (p<0.0001), accounting for 78.4% in 2014 for all subjects. The highest use was found in the youngest children (in 2014: 85.6%), the lowest use in 6-<12 year olds (in 2014: 72.9%). The number of SMBG/day increased from 2.2 to 6.4 with a similar rise in all age-groups (p<0.0001). Frequency was highest in subjects <6yr. CONCLUSIONS: In all age-groups, T1D treatment was intensified over the last 20 years. Age-specific differences in trends were particularly observed in the number of patients on CSII, in the number of patients with 4 or more injections/day, and in the frequency of SMBG/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 5×
“Previous studies investigating trends in diabetes treatment in children and adolescent with type 1 diabetes are limited by a short study period or a low number of documented cases [7], a small country size [6,18], and recent studies were not population-based [10] or not stratified by age [8].”
BackgroundMethodInfluentialCengiz, E., Xing, D., Wong, J. C., Wolfsdorf, J. I., Haymond, M. W., Rewers, A., Shanmugham, S., Tamborlane, W. V., Willi, S. M., Seiple, D. L., et al. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12030 · Cited by 243 · cited 1×
“Medical conditions such as a high risk of hypoglycemia in very young children [9], worse metabolic control or a higher frequency of mental disorders in adolescents [10–12] may lead to different treatment regimens.”
BackgroundCare of diabetes in children and adolescents: controversies, changes, and consensus
Cameron, F. J., & Wherrett, D. K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60971-0 · Cited by 99
Cited by
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Self-citationKarges, B., Schwandt, A., Heidtmann, B., Kordonouri, O., Binder, E., Schierloh, U., Boettcher, C., Kapellen, T., Rosenbauer, J., & Holl, R. W. (2017) · JAMA · doi:10.1001/jama.2017.13994 · Cited by 452
Self-citationAddala, A., Auzanneau, M., Miller, K., Maier, W., Foster, N., Kapellen, T., Walker, A., Rosenbauer, J., Maahs, D. M., & Holl, R. W. (2021) · Diabetes Care · doi:10.2337/dc20-0257 · Cited by 283
Self-citationvan den Boom, L., Karges, B., Auzanneau, M., Rami-Merhar, B., Lilienthal, E., von Sengbusch, S., Datz, N., Schröder, C., Kapellen, T., Laimer, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0345 · Cited by 191
Self-citationNørgaard, K., Sukumar, N., Rafnsson, S. B., & Saravanan, P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0411-7 · Cited by 26
“Funding: Novo Nordisk A/S. Keywords: CSII; Pediatrics; Pregnancy; Rapidacting insulin analogs; Type 1 diabetes”
BackgroundInfluentialCharleer, S., Gillard, P., Vandoorne, E., Cammaerts, K., Mathieu, C., & Casteels, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13128 · Cited by 14
Metadata
- Authors
- Bohn, B., Karges, B., Vogel, C., Otto, K.-P., Marg, W., Hofer, S. E., Fröhlich-Reiterer, E., Holder, M., Plamper, M., Wabitsch, M., Kerner, W., Holl, R. W., & Initiative, D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-08-17
- Volume
- 11
- Issue
- 8
- Pages
- e0160971
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2516659710
- Cited by
- 63
- References
- 4
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.